{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:54:54Z","timestamp":1791302094250,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"DOI":"10.1038\/s41433-026-04939-7","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:52:55Z","timestamp":1791294775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retinoblastoma management: achieving high standards of care"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-3632","authenticated-orcid":false,"given":"Carol L.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salaam","family":"Botros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bechara Ghobril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"4939_CR1","unstructured":"No author. Distribution of major cancer types in children under 15 years of age, 2000s, International Agency for Research on Cancer, sponsored by the World Health Organization, 2018, https:\/\/www.iarc.who.int\/featured-news\/media-centre-iarc-news-childhoodcancer-2016\/2026."},{"key":"4939_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/jamaophthalmol.2015.3108","volume":"133","author":"DH Abramson","year":"2015","unstructured":"Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of retinoblastoma in 2015. Agreement and disagreement. JAMA Ophthalmol. 2015;133:1341\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"4939_CR3","doi-asserted-by":"crossref","unstructured":"Abramson DH, Shields CL, Munier FL, Chantada GL. How we approach retinoblastoma in 2026\u2014Agreement and disagreement in 4 referral centers in the USA and Europe. Ped Blood Cancer. 2026;73:e70401.","DOI":"10.1002\/1545-5017.70401"},{"key":"4939_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/archopht.120.7.923","volume":"120","author":"SG Honavar","year":"2002","unstructured":"Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923\u201331.","journal-title":"Arch Ophthalmol"},{"key":"4939_CR5","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1001\/archophthalmol.2011.289","volume":"129","author":"S Kaliki","year":"2011","unstructured":"Kaliki S, Shields CL, Shah SU, et al. Post-enucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129:1422\u20137.","journal-title":"Arch Ophthalmol"},{"key":"4939_CR6","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1097\/IAE.0000000000001816","volume":"38","author":"S Kaliki","year":"2018","unstructured":"Kaliki S, Shields CL, Eagle RC, et al. High-risk intraocular retinoblastoma: comparison between Asian Indians and Americans from 2 major referral centers. Retina. 2018;38:2023\u201329.","journal-title":"Retina"},{"key":"4939_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ophtha.2024.08.037","volume":"132","author":"VS Vempuluru","year":"2024","unstructured":"Vempuluru VS, Shields CL, Berry JL, Kaliki S. High-risk retinoblastoma collaborative study group. Retinoblastoma outcomes based on the 8th edition American Joint Committee on Cancer Pathological Classification in 1411 Patients. Ophthalmology. 2024;132:317\u201326.","journal-title":"Ophthalmology"},{"key":"4939_CR8","doi-asserted-by":"crossref","unstructured":"Kurian D, Kaliki S, Shields CL. On behalf of the High-Risk Retinoblastoma Collaborative Group. High-risk retinoblastoma based on international classification systems: analysis of 1362 eyes. Ophthalmol Retina. 2025;9:787\u201397.","DOI":"10.1016\/j.oret.2025.01.020"},{"key":"4939_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/APO.0000000000000408","volume":"10","author":"CL Shields","year":"2021","unstructured":"Shields CL, Shields JA. Here comes the sun for retinoblastoma. Asia Pac J Ophthalmol. 2021;10:341\u20132.","journal-title":"Asia Pac J Ophthalmol"},{"key":"4939_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/archopht.1996.01100140521001","volume":"114","author":"BL Gallie","year":"1996","unstructured":"Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114:1321\u20138.","journal-title":"Arch Ophthalmol"},{"key":"4939_CR11","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/archopht.1996.01100140548005","volume":"114","author":"AL Murphree","year":"1996","unstructured":"Murphree AL, Villablanca JC, Deegan WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1348\u201356.","journal-title":"Arch Ophthalmol"},{"key":"4939_CR12","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/archopht.1996.01100140530002","volume":"114","author":"CL Shields","year":"1996","unstructured":"Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1330\u20138.","journal-title":"Arch Ophthalmol"},{"key":"4939_CR13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/archopht.1996.01100140539004","volume":"114","author":"JE Kingston","year":"1996","unstructured":"Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1339\u201343.","journal-title":"Arch Ophthalmol"},{"key":"4939_CR14","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/archopht.1996.01100140612015","volume":"114","author":"FL Ferris","year":"1996","unstructured":"Ferris FL, Chew EY. A new era for the treatment of retinoblastoma. Arch Ophthalmol. 1996;114:1412.","journal-title":"Arch Ophthalmol"},{"key":"4939_CR15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bjophthalmol-2019-314363","volume":"104","author":"CL Shields","year":"2020","unstructured":"Shields CL, Bas Z, Tadepalli S, et al. Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre. Br J Ophthalmol. 2020;104:1548\u201355.","journal-title":"Br J Ophthalmol"},{"key":"4939_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/eye.2012.175","volume":"27","author":"CL Shields","year":"2013","unstructured":"Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular and intravitreal chemotherapy. Eye. 2013;27:253\u201364.","journal-title":"Eye"},{"key":"4939_CR17","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/archopht.119.9.1269","volume":"119","author":"CL Shields","year":"2001","unstructured":"Shields CL, Meadows AT, Shields JA, et al. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol. 2001;119:1269\u201372.","journal-title":"Arch Ophthalmol"},{"key":"4939_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ajo.2013.05.023","volume":"156","author":"A Ramasubramanian","year":"2013","unstructured":"Ramasubramanian A, Kytasty C, Meadows AT, et al. Incidence of pineal gland cyst and pineoblastoma in children with retinoblastoma during the chemoreduction era. Am J Ophthalmol. 2013;156:825\u20139.","journal-title":"Am J Ophthalmol"},{"key":"4939_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.ophtha.2014.01.026","volume":"121","author":"CL Shields","year":"2014","unstructured":"Shields CL, Manjandavida FP, Pieretti G, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the International Classification of Retinoblastoma. Ophthalmology. 2014;121:1453\u201360.","journal-title":"Ophthalmology"},{"key":"4939_CR20","doi-asserted-by":"publisher","first-page":"150.e1","DOI":"10.1016\/j.jaapos.2020.12.006","volume":"25","author":"CL Shields","year":"2021","unstructured":"Shields CL, Dockery PW, Yaghy A, et al. Intra-arterial chemotherapy for retinoblastoma in 341 consecutive eyes (1292 infusions): comparative analysis of outcomes based on patient age, race, and sex. J Aapos. 2021;25:150.e1\u2013150.e9.","journal-title":"J Aapos"},{"key":"4939_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4103\/ijo.IJO_866_19","volume":"67","author":"FP Manjandavida","year":"2019","unstructured":"Manjandavida FP, Stathopoulos C, Zhang J, et al. Intra-arterial chemotherapy in retinoblastoma: A paradigm change. Ind J Ophthalmol. 2019;67:740\u201354.","journal-title":"Ind J Ophthalmol"},{"key":"4939_CR22","first-page":"1","volume":"13","author":"P Jabbour","year":"2012","unstructured":"Jabbour P, Chalouhy N, Tjoumakaris S, et al. Pearls and pitfalls of intra-arterial chemotherapy for retinoblastoma. A review. J Neurosurg Pediatr. 2012;13:1\u20137.","journal-title":"J Neurosurg Pediatr"},{"key":"4939_CR23","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1093\/neuros\/nyaa142","volume":"87","author":"A Sweid","year":"2020","unstructured":"Sweid A, Hammoud B, Texakalidis P, et al. The use of alternative routes for the delivery of intra-arterial chemotherapy for retinoblastoma. Neurosurgery. 2020;87:956\u201363.","journal-title":"Neurosurgery"},{"key":"4939_CR24","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.ophtha.2018.05.013","volume":"125","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA, Ancona-Lezama D, Lucio-Alvarez JA, et al. Ophthalmic vascular events after primary unilateral intra-arterial chemotherapy for retinoblastoma in early and recent eras. Ophthalmology. 2018;125:1803.","journal-title":"Ophthalmology"},{"key":"4939_CR25","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archophthalmol.2012.1983","volume":"130","author":"F Ghassemi","year":"2012","unstructured":"Ghassemi F, Shields CL, Shields JA. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130:1268\u201371.","journal-title":"Arch Ophthalmol"},{"key":"4939_CR26","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","volume":"96","author":"FL Munier","year":"2012","unstructured":"Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96:1078\u201383.","journal-title":"Br J Ophthalmol"},{"key":"4939_CR27","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1097\/IAE.0000000000000903","volume":"36","author":"CL Shields","year":"2016","unstructured":"Shields CL, Douglass A, Beggache M, et al. Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture. Retina. 2016;36:1184\u201390.","journal-title":"Retina"},{"key":"4939_CR28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ophtha.2024.04.022","volume":"131","author":"M Sen","year":"2024","unstructured":"Sen M, Rao R, Mulay K, et al. Intravitreal topotecan for vitreous seeds in retinoblastoma: a long-term review of 91 eyes. Ophthalmology. 2024;131:1215\u201324.","journal-title":"Ophthalmology"},{"key":"4939_CR29","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jamaophthalmol.2017.4600","volume":"135","author":"JH Francis","year":"2017","unstructured":"Francis JH, Abramson DH, Ji X, et al. Risk of extraocular extension in eyes with retinoblastoma receiving intravitreous chemotherapy. JAMA Ophthalmol. 2017;135:1426\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"4939_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2022.109026","volume":"218","author":"MJ Del Sole","year":"2022","unstructured":"Del Sole MJ, Clausse M, Nejamkin P, et al. Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: implications for retinoblastoma treatment. Exp Eye Res. 2022;218:109026.","journal-title":"Exp Eye Res"},{"key":"4939_CR31","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.3928\/01913913-20230110-01","volume":"60","author":"DH Abramson","year":"2023","unstructured":"Abramson DH, Francis JH. Intravitreal topotecan 90 ug for recurrent solid retinoblastoma tumors is effective and not toxic. J Pediatr Ophthalmol Strabismus. 2023;60:e16\u2013e18.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"4939_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000004283","volume":"45","author":"CL Shields","year":"2025","unstructured":"Shields CL, Medina RJ, Evans H, et al. High-dose intravitreal topotecan for recurrent retinoblastoma, subretinal seeds, and vitreous seeds. Retina. 2025;45:1\u20136.","journal-title":"Retina"},{"key":"4939_CR33","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/IAE.0000000000004678","volume":"46","author":"CL Shields","year":"2026","unstructured":"Shields CL, Medina RJ, Attaseth T, Lally SE. Lack of complications of high-dose intravitreal topotecan for recurrent retinoblastoma in 81 consecutive injections. Retina. 2026;46:264\u201371.","journal-title":"Retina"},{"key":"4939_CR34","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1097\/IAE.0000000000004601","volume":"45","author":"VS Vempuluru","year":"2025","unstructured":"Vempuluru VS, Raval V, Kaliki S. High-dose intravitreal topotecan (100 \u00b5g\/0.1 cc) as monotherapy for recurrent\/refractory intraocular retinoblastoma in seven eyes. Retina. 2025;45:2142\u20139.","journal-title":"Retina"},{"key":"4939_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3928\/01913913-20210903-01","volume":"59","author":"M Ruben","year":"2022","unstructured":"Ruben M, Eiger-Moscovich M, Yaghy A, et al. Iodine-125 plaque radiotherapy for retinoblastoma recurrence following intra-arterial chemotherapy. J Pediatr Ophthalmol Strabismus. 2022;59:164\u201371.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"4939_CR36","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1136\/bjophthalmol-2018-312915","volume":"103","author":"JE Lu","year":"2019","unstructured":"Lu JE, Francis JH, Dunkel IJ, et al. Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007\u201317. Br J Ophthalmol. 2019;103:1272\u20137.","journal-title":"Br J Ophthalmol"},{"key":"4939_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000004673","volume":"46","author":"CL Shields","year":"2026","unstructured":"Shields CL, Lally SE, Shah AC. Enucleation of an eye with potential high-risk retinoblastoma is currently important for patient survival. Retina. 2026;46:1\u20133.","journal-title":"Retina"},{"key":"4939_CR38","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1097\/IAE.0000000000004250","volume":"44","author":"S Kaliki","year":"2024","unstructured":"Kaliki S, Vempuluru VS, Rajendra Bakal K, et al. High-risk histopathological features of retinoblastoma following primary enucleation. Retina. 2024;44:2105\u201315.","journal-title":"Retina"},{"key":"4939_CR39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/IAE.0000000000004340","volume":"45","author":"GS Negretti","year":"2025","unstructured":"Negretti GS, Ushakova T, Yuri S, et al. Neovascular glaucoma as a predictor of retinoblastoma high-risk histopathology in an international multicenter study. Retina. 2025;45:565\u201373.","journal-title":"Retina"},{"key":"4939_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.oret.2025.01.020","volume":"9","author":"DE Kurian","year":"2025","unstructured":"Kurian DE, Kaliki S, Shields CL, et al. High-risk retinoblastoma based on international classification systems. Ophthalmol Retina. 2025;9:787\u201397.","journal-title":"Ophthalmol Retina"},{"key":"4939_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4103\/ijo.IJO_352_15","volume":"65","author":"S Honavar","year":"2017","unstructured":"Honavar S, Manjandavida RP, Reddy VA. Orbital retinoblastoma: An update. Indian J Ophthalmol. 2017;65:435\u201342.","journal-title":"Indian J Ophthalmol"},{"key":"4939_CR42","doi-asserted-by":"publisher","first-page":"e1128","DOI":"10.1016\/S2214-109X(22)00250-9","volume":"10","author":"Global Retinoblastoma","year":"2022","unstructured":"Retinoblastoma Global, Group Study. The global retinoblastoma outcome study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Lancet Glob Health. 2022;10:e1128\u2013e1140.","journal-title":"Lancet Glob Health"},{"key":"4939_CR43","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/S2214-109X(21)00555-6","volume":"10","author":"ES Wong","year":"2022","unstructured":"Wong ES, Choy RW, Zhang Y, et al. Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors. Lancet Glob Health. 2022;10:e380\u2013e389.","journal-title":"Lancet Glob Health"},{"key":"4939_CR44","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2023.16875","volume":"330","author":"S Bhatia","year":"2023","unstructured":"Bhatia S, Tonorezos ES, Landier W. Clinical care for people who survive childhood cancer. A review. JAMA. 2023;330:1175\u201386.","journal-title":"JAMA"},{"key":"4939_CR45","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamapediatrics.2023.2168","volume":"177","author":"ARYB Lee","year":"2023","unstructured":"Lee ARYB, Low CE, Yau CE, et al. Lifetime burden of psychological symptoms, disorders, and suicide due to cancer in childhood, adolescent, and young adult years. JAMA Pediatr. 2023;177:790\u20139.","journal-title":"JAMA Pediatr"},{"key":"4939_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2019.05.020","volume":"207","author":"MLZ Collins","year":"2019","unstructured":"Collins MLZ, Bregman J, Ford JS, Shields CL. Depression, anxiety, and stress in parents of patients with retinoblastoma. Am J Ophthalmol. 2019;207:130\u201343.","journal-title":"Am J Ophthalmol"},{"key":"4939_CR47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0002-9394(03)00872-9","volume":"137","author":"K Xu","year":"2004","unstructured":"Xu K, Rosenwaks Z, Beaverson K, et al. Preimplantation genetic diagnosis for retinoblastoma: the first reported liveborn. Am J Ophthalmol. 2004;137:18\u201323.","journal-title":"Am J Ophthalmol"},{"key":"4939_CR48","doi-asserted-by":"crossref","unstructured":"Bechara Ghobril A, Lally SE, Shields CL. From enucleation to prevention: evolution of germline retinoblastoma management. J Pediatr Ophthalmol Strabism. 2026;63:e51-3.","DOI":"10.3928\/01913913-20260810-02"},{"key":"4939_CR49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/ICU.0000000000000091","volume":"25","author":"CL Shields","year":"2014","unstructured":"Shields CL, Lally SE, Leahey AM, et al. Targeted retinoblastoma management. When to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol. 2014;25:374\u201385.","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04939-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:02:30Z","timestamp":1791298950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":49,"alternative-id":["4939"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04939-7","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"29 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}